These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 16768975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 4. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M, Kubácková K, Palágyi M, Smíd M.
    Cas Lek Cesk; 2006 Dec; 145(4):296-300. PubMed ID: 16639930
    [Abstract] [Full Text] [Related]

  • 5. EU orphan regulation--ten years of application.
    Michaux G.
    Food Drug Law J; 2010 Dec; 65(4):639-69, i-ii. PubMed ID: 24479246
    [Abstract] [Full Text] [Related]

  • 6. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME.
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [Abstract] [Full Text] [Related]

  • 7. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G.
    Wall St J (East Ed); 2005 Nov 15; ():A1, A18. PubMed ID: 16502531
    [No Abstract] [Full Text] [Related]

  • 8. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K, Stargardt T, Schreyögg J.
    Gesundheitswesen; 2011 Aug 15; 73(8-9):504-14. PubMed ID: 20848380
    [Abstract] [Full Text] [Related]

  • 9. EU to review rare disease drugs market exclusivity.
    Sheridan C.
    Nat Biotechnol; 2004 Sep 15; 22(9):1061. PubMed ID: 15340455
    [No Abstract] [Full Text] [Related]

  • 10. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May 15; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

  • 11. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 12. Rare diseases and orphan drugs.
    Taruscio D, Capozzoli F, Frank C.
    Ann Ist Super Sanita; 2011 Jan 19; 47(1):83-93. PubMed ID: 21430345
    [Abstract] [Full Text] [Related]

  • 13. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR, van Veldhuizen CK, de Vries PJ.
    Ned Tijdschr Geneeskd; 2012 Jan 19; 156(17):A4252. PubMed ID: 22531041
    [Abstract] [Full Text] [Related]

  • 14. Access to orphan drugs in Europe: current and future issues.
    Michel M, Toumi M.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb 19; 12(1):23-9. PubMed ID: 22280193
    [Abstract] [Full Text] [Related]

  • 15. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA, Freeman SN, Imoisili MA, Coté TR.
    Clin Pharmacol Ther; 2010 Oct 19; 88(4):449-53. PubMed ID: 20856241
    [Abstract] [Full Text] [Related]

  • 16. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I, Breckenridge A.
    Clin Pharmacol Ther; 2012 Aug 19; 92(2):151-3. PubMed ID: 22814659
    [Abstract] [Full Text] [Related]

  • 17. Should off-label drug use be off-the-table?
    Rivkees SA.
    J Pediatr Endocrinol Metab; 2007 Feb 19; 20(2):171-2. PubMed ID: 17396432
    [No Abstract] [Full Text] [Related]

  • 18. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN, Williams CS, Arrowsmith JE.
    Drug Discov Today; 2012 Jul 19; 17(13-14):660-4. PubMed ID: 22366309
    [Abstract] [Full Text] [Related]

  • 19. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW, Lilitkarntakul P, Webb DJ.
    Br J Clin Pharmacol; 2006 Sep 19; 62(3):264-71. PubMed ID: 16934041
    [Abstract] [Full Text] [Related]

  • 20. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S.
    Mol Interv; 2006 Aug 19; 6(4):186-91. PubMed ID: 16960139
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.